477 related articles for article (PubMed ID: 10406804)
21. Wilms' tumor gene WT1-shRNA as a potent apoptosis-inducing agent for solid tumors.
Tatsumi N; Oji Y; Tsuji N; Tsuda A; Higashio M; Aoyagi S; Fukuda I; Ito K; Nakamura J; Takashima S; Kitamura Y; Miyai S; Jomgeow T; Li Z; Shirakata T; Nishida S; Tsuboi A; Oka Y; Sugiyama H
Int J Oncol; 2008 Mar; 32(3):701-11. PubMed ID: 18292948
[TBL] [Abstract][Full Text] [Related]
22. Regulation of insulin-like growth factor I receptor promoter activity by wild-type and mutant versions of the WT1 tumor suppressor.
Tajinda K; Carroll J; Roberts CT
Endocrinology; 1999 Oct; 140(10):4713-24. PubMed ID: 10499530
[TBL] [Abstract][Full Text] [Related]
23. Prognostic significance of Bcl-2 in Wilms' tumor and oncogenic potential of Bcl-X(L) in rare tumor cases.
Re GG; Hazen-Martin DJ; El Bahtimi R; Brownlee NA; Willingham MC; Garvin AJ
Int J Cancer; 1999 Apr; 84(2):192-200. PubMed ID: 10096254
[TBL] [Abstract][Full Text] [Related]
24. The Wilms' tumor suppressor, WT1, inhibits 12-O-tetradecanoylphorbol-13-acetate activation of the multidrug resistance-1 promoter.
McCoy C; McGee SB; Cornwell MM
Cell Growth Differ; 1999 Jun; 10(6):377-86. PubMed ID: 10392899
[TBL] [Abstract][Full Text] [Related]
25. Wilms tumor and the WT1 gene.
Lee SB; Haber DA
Exp Cell Res; 2001 Mar; 264(1):74-99. PubMed ID: 11237525
[TBL] [Abstract][Full Text] [Related]
26. Wilms' tumor 1-KTS isoforms induce p53-independent apoptosis that can be partially rescued by expression of the epidermal growth factor receptor or the insulin receptor.
Menke AL; Shvarts A; Riteco N; van Ham RC; van der Eb AJ; Jochemsen AG
Cancer Res; 1997 Apr; 57(7):1353-63. PubMed ID: 9102224
[TBL] [Abstract][Full Text] [Related]
27. Oxygen-regulated expression of the Wilms' tumor suppressor Wt1 involves hypoxia-inducible factor-1 (HIF-1).
Wagner KD; Wagner N; Wellmann S; Schley G; Bondke A; Theres H; Scholz H
FASEB J; 2003 Jul; 17(10):1364-6. PubMed ID: 12738801
[TBL] [Abstract][Full Text] [Related]
28. CTNNB1 mutations and overexpression of Wnt/beta-catenin target genes in WT1-mutant Wilms' tumors.
Li CM; Kim CE; Margolin AA; Guo M; Zhu J; Mason JM; Hensle TW; Murty VV; Grundy PE; Fearon ER; D'Agati V; Licht JD; Tycko B
Am J Pathol; 2004 Dec; 165(6):1943-53. PubMed ID: 15579438
[TBL] [Abstract][Full Text] [Related]
29. Analysis of WT1 target gene expression in stably transfected cell lines.
Thäte C; Englert C; Gessler M
Oncogene; 1998 Sep; 17(10):1287-94. PubMed ID: 9771972
[TBL] [Abstract][Full Text] [Related]
30. Expression of WT1 protein in fetal kidneys and Wilms tumors.
Grubb GR; Yun K; Williams BR; Eccles MR; Reeve AE
Lab Invest; 1994 Oct; 71(4):472-9. PubMed ID: 7967503
[TBL] [Abstract][Full Text] [Related]
31. Wilms' tumor protein (-KTS) modulates renin gene transcription.
Steege A; Fähling M; Paliege A; Bondke A; Kirschner KM; Martinka P; Kaps C; Patzak A; Persson PB; Thiele BJ; Scholz H; Mrowka R
Kidney Int; 2008 Aug; 74(4):458-66. PubMed ID: 18496514
[TBL] [Abstract][Full Text] [Related]
32. Midkine as a novel target gene for the Wilms' tumor suppressor gene (WT1).
Adachi Y; Matsubara S; Pedraza C; Ozawa M; Tsutsui J; Takamatsu H; Noguchi H; Akiyama T; Muramatsu T
Oncogene; 1996 Nov; 13(10):2197-203. PubMed ID: 8950987
[TBL] [Abstract][Full Text] [Related]
33. Transcriptional repression of human insulin-like growth factor-II P4 promoter by Wilms' tumor suppressor WT1.
Lee YI; Kim SJ
DNA Cell Biol; 1996 Feb; 15(2):99-104. PubMed ID: 8634146
[TBL] [Abstract][Full Text] [Related]
34. The Wilms' tumor suppressor WT1: approaches to gene function.
Menke A; McInnes L; Hastie ND; Schedl A
Kidney Int; 1998 Jun; 53(6):1512-8. PubMed ID: 9607183
[TBL] [Abstract][Full Text] [Related]
35. Human platelet-derived growth factor A chain is transcriptionally repressed by the Wilms tumor suppressor WT1.
Gashler AL; Bonthron DT; Madden SL; Rauscher FJ; Collins T; Sukhatme VP
Proc Natl Acad Sci U S A; 1992 Nov; 89(22):10984-8. PubMed ID: 1332065
[TBL] [Abstract][Full Text] [Related]
36. Overlapping RNA and DNA binding domains of the wt1 tumor suppressor gene product.
Bardeesy N; Pelletier J
Nucleic Acids Res; 1998 Apr; 26(7):1784-92. PubMed ID: 9512553
[TBL] [Abstract][Full Text] [Related]
37. Upregulation of c-MYC in WT1-mutant tumors: assessment of WT1 putative transcriptional targets using cDNA microarray expression profiling of genetically defined Wilms' tumors.
Udtha M; Lee SJ; Alam R; Coombes K; Huff V
Oncogene; 2003 Jun; 22(24):3821-6. PubMed ID: 12802290
[TBL] [Abstract][Full Text] [Related]
38. WT1 splicing alterations in Wilms' tumors.
Baudry D; Hamelin M; Cabanis MO; Fournet JC; Tournade MF; Sarnacki S; Junien C; Jeanpierre C
Clin Cancer Res; 2000 Oct; 6(10):3957-65. PubMed ID: 11051244
[TBL] [Abstract][Full Text] [Related]
39. Products of alternatively spliced transcripts of the Wilms' tumor suppressor gene, wt1, have altered DNA binding specificity and regulate transcription in different ways.
Wang ZY; Qiu QQ; Huang J; Gurrieri M; Deuel TF
Oncogene; 1995 Feb; 10(3):415-22. PubMed ID: 7845666
[TBL] [Abstract][Full Text] [Related]
40. The Wilms' tumor suppressor Wt1 activates transcription of the erythropoietin receptor in hematopoietic progenitor cells.
Kirschner KM; Hagen P; Hussels CS; Ballmaier M; Scholz H; Dame C
FASEB J; 2008 Aug; 22(8):2690-701. PubMed ID: 18424770
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
